Charles River Laboratories, International Inc. announced it has received regulatory approval, in the form of Good Manufacturing Practice (GMP) certification, to commercially produce allogeneic cell therapy drug products for distribution in Europe, from the European Medicines Agency (EMA). The approval follows an inspection by the cell and gene therapy experts from the Italian inspectorate, Agenzia […]

The post Charles River Receives EMA Approval to Produce Allogeneic Cell Therapy first appeared on World Pharma Today.